Attovia Therapeutics, Inc. (ATTO)
22.93
-0.73
(-3.09%)
USD |
NASDAQ |
Sep 09, 16:00
22.93
0.00 (0.00%)
After-Hours: 17:07
Attovia Therapeutics Enterprise Value : 1.228B for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 1.228B |
| September 04, 2026 | 1.314B |
| September 03, 2026 | 1.252B |
| September 02, 2026 | 1.203B |
| September 01, 2026 | 1.162B |
| August 31, 2026 | 1.124B |
| August 28, 2026 | 1.092B |
| August 27, 2026 | 1.127B |
| August 26, 2026 | 1.040B |
| August 25, 2026 | 1.029B |
| August 24, 2026 | 1.089B |
| August 21, 2026 | 1.097B |
| August 20, 2026 | 1.070B |
| Date | Value |
|---|---|
| August 19, 2026 | 1.158B |
| August 18, 2026 | 1.208B |
| August 17, 2026 | 1.184B |
| August 14, 2026 | 1.054B |
| August 13, 2026 | 1.023B |
| August 12, 2026 | 971.88M |
| August 11, 2026 | 998.82M |
| August 10, 2026 | 1.053B |
| August 07, 2026 | 1.068B |
| August 06, 2026 | 1.078B |
| August 05, 2026 | 1.147B |
| August 04, 2026 | 923.49M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Agenus, Inc. | 581.29M |
| Amgen, Inc. | 255.86B |
| Anika Therapeutics, Inc. | 268.42M |
| BioCryst Pharmaceuticals, Inc. | 2.798B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.69M |
| Revenue (Quarterly) | 0.45M |
| Total Expenses (Quarterly) | 21.14M |
| EPS Diluted (Quarterly) | -0.4532 |
| Gross Profit Margin (Quarterly) | 45.33% |
| Profit Margin (Quarterly) | -4.60K% |
| Earnings Yield | -6.61% |
| Normalized Earnings Yield | -6.600 |